Borosil Scientific Ltd Q1 FY26 – The Lab Coat Smallcap with 4,000 SKUs, 200-Day Inventory, and a P/E Hotter than a Bunsen Burner
1. At a Glance
Meet Borosil Scientific Ltd (BSL) – market cap ₹1,232 crore, CMP ₹138, and a P/E of 51.3 (yes, the stock is priced like it’s selling iPhones, not test tubes). Listed in June 2024 after a demerger from Borosil Ltd, this labware company brings in ~₹430 crore sales and ₹24 crore PAT. But Q1 FY26 was a full-on lab accident: sales slipped 8% QoQ to ₹96 crore, PAT halved to ₹2.25 crore (down 55% YoY). ROCE? 10.3%. ROE? 6.9%. Basically, the return profile of a government bond, but with the volatility of crypto.
2. Introduction
Picture this: a company famous for its sturdy lab glassware, now standing in front of investors saying, “Trust me, I’ve been here since 1962.” Yes, Borosil is older than most SEBI officials. But age alone doesn’t guarantee market love.
Borosil Scientific was carved out of Borosil Ltd in FY24 to give its scientific and packaging business a standalone identity. Management probably hoped investors would say, “Wow, pure play lab equipment!” Instead, investors said, “Beta, why are you trading at 51x earnings when your margins look like half-baked dosa?”
The company serves pharma giants (61% of revenues), universities (13%), and research institutes (14%). Great clientele, but execution? That’s like IIT-JEE students writing in SMS lingo – lots of potential, but questionable output.
3. Business Model – WTF Do They Even Do?
This one’s fun:
Scientific Segment (65% of revenues): Glassware, lab equipment (LabQuest brand), and process systems. They even acquired Goel Scientific to boost credibility in process reactors. Basically, if your chemistry lab had nice beakers, it’s probably theirs.
Glassware Segment (35%): Pharma packaging (ampoules, vials) and domestic kitchen glassware. Because why not confuse investors with a hybrid model – one SKU goes to Cipla, the other to your mom’s pickle jars.
Facilities in Vadodara, Bharuch, Pune, and Nashik churn out 45,000 labware units/day, 350 mn vials/year, and 800 mn ampoules/year. With 4,000+ SKUs and 150 distributors, they sell in 90+ countries.
Detective lens: Looks good on paper, but margins are thin. Scientific gear is growing, pharma packaging is competitive, and consumer glassware is a brutal market (ask La Opala or Borosil’s cousin companies).
4. Financials Overview
Quarterly Snapshot (₹ Cr):
Source table
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
96.0
104.2
129.5
-7.9%
-25.8%
EBITDA
4.9
9.8
16.6
-50.5%
-70.7%
PAT
2.3
5.0
8.6
-55.3%
-73.8%
EPS (₹)
0.25
0.57
0.97
-56.1%
-74.2%
Annualised EPS = 0.25 × 4 = ₹1.0. CMP ₹138 → P/E ~138x (screener’s TTM shows 51x, but annualised Q1 tells us the lab is on fire).
Commentary: If Q1 repeats, investors are effectively paying for 22 years of earnings upfront. Even Jeff Bezos wouldn’t dare pitch that.
5. Valuation Discussion – Fair Value Range Only
P/E Method: TTM EPS = ₹1.98. At industry P/E = 25 → Fair value ~₹50. At high-growth optimism P/E
